Impact of SARS-CoV-2 vaccination of children ages 5–11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: a multi-model study

Summary Background SARS-CoV-2 vaccination of persons aged 12 years and older has reduced disease burden in the United States. The COVID-19 Scenario Modeling Hub convened multiple modeling teams in September 2021 to project the impact of expanding vaccine administration to children 5–11 years old on anticipated COVID-19 burden and resilience against variant strains. Methods Nine modeling teams contributed state- and national-level projections for weekly counts of cases, hospitalizations, and deaths in the United States for the period September 12, 2021 to March 12, 2022. Four scenarios covered all combinations of: 1) presence vs. absence of vaccination of children ages 5–11 years starting on November 1, 2021; and 2) continued dominance of the Delta variant vs. emergence of a hypothetical more transmissible variant on November 15, 2021. Individual team projections were combined using linear pooling. The effect of childhood vaccination on overall and age-specific outcomes was estimated by meta-analysis approaches. Findings Absent a new variant, COVID-19 cases, hospitalizations, and deaths among all ages were projected to decrease nationally through mid-March 2022. Under a set of specific assumptions, models projected that vaccination of children 5–11 years old was associated with reductions in all-age cumulative cases (7.2%, mean incidence ratio [IR] 0.928, 95% confidence interval [CI] 0.880–0.977), hospitalizations (8.7%, mean IR 0.913, 95% CI 0.834–0.992), and deaths (9.2%, mean IR 0.908, 95% CI 0.797–1.020) compared with scenarios where children were not vaccinated. This projected effect of vaccinating children 5–11 years old increased in the presence of a more transmissible variant, assuming no change in vaccine effectiveness by variant. Larger relative reductions in cumulative cases, hospitalizations, and deaths were observed for children than for the entire U.S. population. Substantial state-level variation was projected in epidemic trajectories, vaccine benefits, and variant impacts. Conclusions Results from this multi-model aggregation study suggest that, under a specific set of scenario assumptions, expanding vaccination to children 5–11 years old would provide measurable direct benefits to this age group and indirect benefits to the all-age U.S. population, including resilience to more transmissible variants.

Five teams did not include waning (CU-AGE-ST, JHUAPL-Bucky, JHU_IDD-CovidSP, UNCChierbin, NotreDame-FRED, see above list of participating teams for full team names). Three teams assumed that immunity would wane exponentially with an average period of either six months (UVA-EpiHiper) or one year (MOBS_NEU-GLEAM-COVID, UVA-adaptive). The USC-SlkJalpha team assumed a weighted average of assumptions about waning.
Five teams also submitted projections with the same quantile structure for a younger age-group (0-11, 5-11, 5-17, and 0-17 year groups) and an older age-group when possible: • CU-AGE-ST • MOBS_NEU-GLEAM_COVID • USC-SlkJalpha • UVA-adaptive • UVA-EpiHiper For scenarios without the emergence of a more transmissible variant, mean reported case reductions in younger age-groups ranged from 6.5 to 34.5% across models over the November 1, 2021 to March 12, 2022 time period. Reductions in hospitalizations and deaths ranged from 5.6 to 34.5% and 5.2 to 34.5%, respectively. For scenarios with the emergence of a more transmissible variant, mean projected reductions in cases were 10.9 to 32.9%, with hospitalization and death reductions ranging from 9.0 to 32.9% and 5.9 to 33.1% respectively. Percent reductions were not estimated for one team, which reported zero deaths for the younger age-group over the November 1, 2021 to March 12, 2022 time period.

Meta analyses
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 10, 2022. ; To summarize the projected benefits of the vaccine program expansion across all modeling teams, we used a standard meta-analytic approach with random effects 22 . We estimated the mean difference in cumulative incidence and the mean incidence ratio between scenarios with and without children 5-11 years old vaccinated, stratified by presence or absence of the new variant, for the portion of the projection period following the assumed start date of childhood vaccination (i.e., from November 1, 2021).
Specifically, for each scenario = , , , , the modeling teams = 1,2,3 . . . 9 directly provided us with the the mean and variance (over their individual model replicates) of each cumulative outcome = , , ℎ , at the start of the vaccination period ( ! ) and the end of the of projection period ( " ) at the national level. We then estimated the mean ( ) and variance ( # ) for each model, scenario, and cumulative incidences over the period of interest as respectively. To compare scenarios, for example A (with vaccination of children 5-11 years old) and B (without vaccination of children 5-11 years old), we then estimated the mean of the difference as $'& − $(& and the variance of the difference as We also estimated the incidence ratio as the ratio of the above means (e.g.
, with the proportion reduction due to the vaccine estimated as 1- ; the variance of this ratio was obtained using the delta method. For both absolute difference and incidence ratio, we estimated the standard error (SE) as @ * # / , where * # is the variance as defined above, and is the number of replicates (simulations or sets of projected outcomes) for that model. Model specific means and standard errors were combined via random effects meta-analysis using restricted maximum likelihood (REML).
At the state level, individual modeling teams provided quantile distributions, as specified above, but did not provide us with model-specific estimates of mean and variance over their replicates at the two above time points of interest. Therefore, to evaluate vaccine benefits at the state level, we estimated the mean and variance from the 23 available points from each modelspecific cumulative distribution function (CDF) at ! and " (again, for each outcome, scenario, and state). Specifically, to each CDF (n~11,000; 51 states x 9 models x 3 outcomes x 4 scenarios x 2 timepoints) we fit a penalized cubic spline Poisson regression model to estimate a continuous quantile function, from which we simulated 25,000 replicates. The mean and variance of these replicates were then estimated, and the above-described approaches were followed to obtain mean and variance for the absolute difference and incidence ratio between scenarios, and for combining these using random effects REML meta analyses. This procedure was also followed for approximating the direct effect of vaccine expansion (within the younger age group).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22271905 doi: medRxiv preprint Figure S1: Model-specific trajectories for cases, hospitalizations, and deaths in each of the four scenarios. Differences between models were generally most apparent in the new variant scenarios. USC-SlkJalpha projected a large peak in cases in early 2022 in the variant scenarios. This peak was followed by peaks in hospitalizations and deaths. NEU-MOBs projected less of an impact in variant scenarios, with deep troughs observed at the nationallevel in early 2022. UVA-EpiHiper projected sharp decreases at the end of December 2021 and resurgences in the post-holiday period, driven by assumptions about school closures.

Supplemental Figures/Tables:
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22271905 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22271905 doi: medRxiv preprint Figure S2: State-level estimates for number of vaccinated 5-11 year olds per capita vs. projected cases occurring between November 1, 2021 and March 12, 2022. Estimates for vaccinated 5-11 year olds are based on the vaccination coverage of 12-17 year olds on September 11, 2021 (the last day of data available for use in projections).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22271905 doi: medRxiv preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22271905 doi: medRxiv preprint